Tim Knotnerus

Chief Executive Officer at AGOMAB THERAPEUTICS NV

Net worth: 508 691 $ as of 31/05/2026

Health Technology

Consumer Services

Finance

Profile

Tim Knotnerus is currently Chief Executive Officer & Executive Director at AgomAb Therapeutics NV since 2021, with employment at the firm starting in 2019.
Formerly, Dr. Knotnerus was Vice President-Corporate Development at AM-Pharma BV from 2012 to 2020 and Senior Associate at Aescap Venture Management BV from 2011 to 2012.
Dr. Knotnerus completed an MBA at the International Institute for Management Development.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
AGOMAB THERAPEUTICS NV 0.09%	18/03/2026	45,217 ( 0.09% )	508 691 $	31/05/2026

Tim Knotnerus active positions

Companies	Position	Start
AGOMAB THERAPEUTICS NV	Chief Executive Officer	01/02/2019

All active positions of Tim Knotnerus

Former positions of Tim Knotnerus

Companies	Position	End
AM-Pharma BV AM-Pharma BV BiotechnologyHealth Technology Provides biopharmaceutical products	Corporate Officer/Principal	01/04/2020
Aescap Venture Management BV Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure.	Private Equity Analyst	31/05/2012

See the detail of Tim Knotnerus's experience

Training of Tim Knotnerus

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Tim Knotnerus's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
International Institute for Management Development International Institute for Management Development Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Aescap Venture Management BV Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure.	Finance
AM-Pharma BV AM-Pharma BV BiotechnologyHealth Technology Provides biopharmaceutical products	Health Technology
AgomAb Therapeutics NV AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues	Health Technology